scholarly journals Development of Hypothyroidism with Thyroid Stimulation Blocking Antibody long after Treatment with Antithyroid Drugs in a Patient with Hyperthyroid Graves' Disease: A Case Report.

1993 ◽  
Vol 40 (2) ◽  
pp. 227-230 ◽  
Author(s):  
YOSHIO KASUGA ◽  
AKIRA SUGENOYA ◽  
SHINYA KOBAYASHI ◽  
TADAHIRO SHIMIZU ◽  
HIROSHI ONUMA ◽  
...  
Keyword(s):  
Case Report ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Blocking Antibody

scholarly journals Coexistence of Primary Hyperaldosteronism and Graves’ Disease, a Rare Combination of Endocrine Disorders: Is It beyond a Coincidence—A Case Report and Review of the Literature

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
S. S. C. Gunatilake ◽  
U. Bulugahapitiya
Keyword(s):  
Case Report ◽  
Adrenal Adenoma ◽  
Underlying Mechanism ◽  
Secondary Hypertension ◽  
Primary Hyperaldosteronism ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Endocrine Disorders ◽  
Sri Lankan ◽  
Underlying Mechanisms

Background. Primary hyperaldosteronism is a known cause for secondary hypertension. In addition to its effect on blood pressure, aldosterone exhibits proinflammatory actions and plays a role in immunomodulation/development of autoimmunity. Recent researches also suggest significant thyroid dysfunction among patients with hyperaldosteronism, but exact causal relationship is not established. Autoimmune hyperthyroidism (Graves’ disease) and primary hyperaldosteronism rarely coexist but underlying mechanisms associating the two are still unclear.Case Presentation. A 32-year-old Sri Lankan female was evaluated for new onset hypertension in association with hypokalemia. She also had features of hyperthyroidism together with high TSH receptor antibodies suggestive of Graves’ disease. On evaluation of persistent hypokalemia and hypertension, primary hyperaldosteronism due to right-sided adrenal adenoma was diagnosed. She was rendered euthyroid with antithyroid drugs followed by right-sided adrenalectomy. Antithyroid drugs were continued up to 12 months, after which the patient entered remission of Graves’ disease.Conclusion. Autoimmune hyperthyroidism and primary hyperaldosteronism rarely coexist and this case report adds to the limited number of cases documented in the literature. Underlying mechanism associating the two is still unclear but possibilities of autoimmune mechanisms and autoantibodies warrant further evaluation and research.

scholarly journals HIPERTIROIDISMEE GRAVES DISEASE:CASE REPORT

2020 ◽  
Vol 6 (1) ◽  
pp. 30-35
Author(s):  
Putri Rahayu Srikandi
Keyword(s):  
Case Report ◽  
Thyroid Hormone ◽  
Thyroid Gland ◽  
Physical Examination ◽  
Clinical Condition ◽  
Laboratory Tests ◽  
Clinical Manifestations ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Thyroid Hormone Levels

AbstractAbstrak:Hipertiroid adalah kondisi klinis yang disebabkan peningkatan sintesis dan sekresi hormone oleh kelenjar tiroid, sedangkan tirotoksikosis mengacu pada manifestasi klinis.  Penyakit graves merupakan penyebab hipertiroid yang paling sering ditemukan sekitar 60-80% dari semua kasus tirotoksikosis di seluruh dunia. Pada laporan kasus ini akan dibahas pasien Ny. NMS berusia 56 tahun datang dengan keluhan dada berdebar-debar yang dirasakan sejak 3 minggu yang lalu dan pada pemeriksaan fisik didapatkan adanya pembesaran kelenjar tiroid dan indeks Wayne pada kasus ini didapatkan  21. Pada pemeriksaan laboratorium didapatkan kadar Tyroid Stimulating Hormone (TSH) 0,005 uIU/ml, , dan free Tiroksin (fT4) 7,77mg/dl. Penatalaksanaan pada kasus ini yaitu pasien diberikan tyrozol  3x10 mg sehari dan propanolol 3x10mg. Kata kunci: graves, hipertiroidism, tirotoksikosis AbstractHipertiroidisme is a clinical condition caused by increased synthesis and secretion of hormones by the thyroid gland. Thyrotoxicosis is defined as clinical manifestations related to increased thyroid hormone levels. Graves' disease (GD) persists as the most frequently encountered etiology of hipertiroidisme causing approximately 60-80% of all cases of thyrotoxicosis worldwide. In this case report we will discuss woman patient Mrs.NMS aged 56 years with complaints of palpitations felt since three weeks ago and physical examination found enlargement of the thyroid gland and Wayne index in this case obtained 21. In laboratory tests found levels of TSH 0.005 uIU/ml and T4 7.77 mg/dl. Principle in the treatment of hipertiroidisme is suppressing the production of thyroid hormone by using antithyroid drugs. Management in this case that the patient is given 3x10 mg Thyrozol and propranolol 3x10 mg. Keywords: graves, hipertiroidisme, thyrotoxicosis

Guideline for radioiodine therapy for benign thyroid diseases (version 3)

2004 ◽  
Vol 43 (06) ◽  
pp. 217-220 ◽  
Author(s):  
J. Dressler ◽  
F. Grünwald ◽  
B. Leisner ◽  
E. Moser ◽  
Chr. Reiners ◽  
...  
Keyword(s):  
Radioiodine Therapy ◽  
Thyroid Volume ◽  
Thyroid Diseases ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Co Morbidity ◽  
History Of ◽  
Individual Decisions ◽  
Prophylactic Use ◽  
Benign Thyroid

SummaryThe version 3 of the guideline for radioiodine therapy for benign thyroid diseases presents first of all a revision of the version 2. The chapter indication for radioiodine therapy, surgical treatment or antithyroid drugs bases on an interdisciplinary consensus. The manifold criteria for decision making consider the entity of thyroid disease (autonomy, Graves’ disease, goitre, goitre recurrence), the thyroid volume, suspicion of malignancy, cystic nodules, risk of surgery and co-morbidity, history of subtotal thyroidectomy, persistent or recurrent thyrotoxicosis caused by Graves’ disease including known risk factors for relapse, compression of the trachea caused by goitre, requirement of direct therapeutic effect as well as the patient’s preference. Because often some of these criteria are relevant, the guideline offers the necessary flexibility for individual decisions. Further topics are patients’ preparation, counseling, dosage concepts, procedural details, results, side effects and follow-up care. The prophylactic use of glucocorticoids during radioiodine therapy in patients without preexisting ophthalmopathy as well as dosage and duration of glucocorticoid medication in patients with preexisting ophthalmopathy need to be clarified in further studies. The pragmatic recommendations for the combined use of radioiodine and glucocorticoids remained unchanged in the 3rd version.

Coexistence of Graves' disease and unilateral benign struma ovarii: A case report

2017 ◽  
Author(s):  
Rosa Marquez-Pardo ◽  
Lourdes Garcia-Garcia-Doncel ◽  
Mgloria Baena-Nieto ◽  
Manuel Cayon-Blanco ◽  
Rosario Lopez-Velasco ◽  
...  
Keyword(s):  
Case Report ◽  
Graves Disease ◽  
Struma Ovarii

Graves' disease and radioiodine therapy

2008 ◽  
Vol 47 (04) ◽  
pp. 153-166 ◽  
Author(s):  
I. Weber ◽  
W. Eschner ◽  
F. Sudbrock ◽  
M. Schmidt ◽  
M. Dietlein ◽  
...  
Keyword(s):  
Success Rate ◽  
Thyroid Function ◽  
Therapeutic Dose ◽  
Radioiodine Therapy ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Inclusion Criteria ◽  
End Point ◽  
Point Measure ◽  
The Impact

SummaryAim: This study was performed to analyse the impact of the choice of antithyroid drugs (ATD) on the outcome of ablative radioiodine therapy (RIT) in patients with Graves' disease. Patients, material, methods: A total of 571 consecutive patients were observed for 12 months after RIT between July 2001 and June 2004. Inclusion criteria were the confirmed diagnosis of Graves' disease, compensation of hyperthyroidism and withdrawal of ATD two days before preliminary radioiodine-testing and RIT. The intended dose of 250 Gy was calculated from the results of the radioiodine test and the therapeutically achieved dose was measured by serial uptake measurements. The end-point measure was thyroid function 12 months after RIT; success was defined as elimination of hyperthyroidism. The pretreatment ATD was retrospectively correlated with the results achieved. Results: Relief from hyperthyroidism was achieved in 96 % of patients. 472 patients were treated with carbimazole or methimazole (CMI) and 61 with propylthiouracil (PTU). 38 patients had no thyrostatic drugs (ND) prior to RIT. The success rate was equal in all groups (CMI 451/472; PTU 61/61; ND 37/38; p=0.22). Conclusion: Thyrostatic treatment with PTU achieves excellent results in ablative RIT, using an accurate dosimetric approach with an achieved post-therapeutic dose of more than 200 Gy.

Effects of high and low doses of methimazole in patients with Graves' thyrotoxicosis

1987 ◽  
Vol 116 (1_Suppl) ◽  
pp. S312-S317 ◽  
Author(s):  
G. Benker ◽  
D. Reinwein ◽  
H. Creutzig ◽  
H. Hirche ◽  
W. D. Alexander ◽  
...  
Keyword(s):  
Antithyroid Drug ◽  
Drug Dosage ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Duration Of Treatment ◽  
Disease Heterogeneity ◽  
Remission Rates ◽  
Set Up ◽  
The Many ◽  
The Impact

Abstract. In spite of the long-established use of antithyroid drugs, there are many unsettled questions connected with this treatment of Graves' disease. There is a lack of controlled prospective trials studying the results of antithyroid drug therapy while considering the many variables such as disease heterogeneity, regional differences, drug dosage and duration of treatment. Therefore, a multicenter study has been set up in order to compare the effects of two fixed doses of methimazole (10 vs 40 mg) with thyroid hormone supplementation on the clinical, biochemical and immunological course of Graves' disease and on remission rates. Experience accumulated so far suggests that treatment is safe using either 10 or 40 mg of methimazole. While there is a tendency for an advantage of the higher dose within the first weeks (higher effectiveness in controlling hyperthyroidism), this difference is not significant. The impact of dosage on remission rates remains to be shown.

scholarly journals The Presence of Thyroid-Stimulation Blocking Antibody Prevents High Bone Turnover in Untreated Premenopausal Patients with Graves’ Disease

PLoS ONE ◽  
2015 ◽  
Vol 10 (12) ◽  
pp. e0144599 ◽  
Author(s):  
Sun Wook Cho ◽  
Jae Hyun Bae ◽  
Gyeong Woon Noh ◽  
Ye An Kim ◽  
Min Kyong Moon ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Graves Disease ◽  
Blocking Antibody ◽  
High Bone Turnover ◽  
High Bone ◽  
Premenopausal Patients

Comparison of body composition and insulin sensitivity changes in patients with Graves disease after radioiodine or antithyroid drugs treatment

2021 ◽  
Author(s):  
Szczepanska Ewa ◽  
Piotr Glinicki ◽  
Zgliczynski Wojciech ◽  
Jastrzębska Helena ◽  
Slowinska-Srzednicka Jadwiga ◽  
...  
Keyword(s):  
Body Composition ◽  
Insulin Sensitivity ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Sensitivity Changes
Sign in / Sign up

Export Citation Format

Share Document